TMS (Synonyms: 2,3',4,5'Tetramethoxystilbene) |
Catalog No.GC15445
One-Click Copy Product Info
|
TMS (2,3′,4,5′-tetramethoxystilbene) is a specific and powerful CYP1B1 inhibitor, with an IC50 value of 6±2nmol/L.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 24144-92-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
TMS (2,3′,4,5′-tetramethoxystilbene) is a specific and powerful CYP1B1 inhibitor, with an IC50 value of 6±2nmol/L[1]. TMS has been used in CYP1B1 enzyme activity studies and in screening and comparative studies of TMS analogues[2].
In vitro, TMS(0-20μmol/L) significantly inhibited 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-stimulated CYP1B1 protein and mRNA expression in a concentration-dependent manner in MCF-7, MCF-10A and HL-60 cells after 24 hours of incubation[3]. TMS (10μmol/L) treatment for 72 hours significantly inhibited the viability of MDA-MB-231 cells and induced cell apoptosis[4]. TMS (20μmol/L) treatment for 48 hours caused an increase in the level of cell cycle inhibitor p27kip1 and promoted the apoptosis of PC-3 prostate cancer cells[5].
In vivo, TMS, intraperitoneal injection of 300μg/kg every 3 days, normalized blood pressure in a rat model of hypertension, reduced CYP1B1 activity, inhibited cardiovascular and renal hypertrophy, and prevented increased vascular reactivity and endothelial dysfunction[6]. Daily treatment with TMS (600μg/kg; i.p.) for 6 weeks reduced the production of reactive oxygen species (ROS) and the increase in NADPH oxidase activity, and inhibited the increase in proinflammatory cytokines and catecholamines in spontaneously hypertensive rats (SHR), accompanied by the decreased plasma levels of inflammatory cytokines[7].
References:
[1]Kim S, Ko H, Park J E, et al. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors[J]. Journal of medicinal chemistry, 2002, 45(1): 160-164.
[2]Chun Y J, Oh Y K, Kim B J, et al. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene[J]. Toxicology letters, 2009, 189(1): 84-89.
[3]Chun Y J, Lee S K, Kim M Y. Modulation of human cytochrome P450 1B1 expression by 2, 4, 3′, 5′-tetramethoxystilbene[J]. Drug metabolism and disposition, 2005, 33(12): 1771-1776.
[4]Chae Y S, Kim J G, Jung H J, et al. Anticancer effect of (E)-2-hydroxy-3′, 4, 5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization[J]. Cancer chemotherapy and pharmacology, 2011, 68: 349-358.
[5]Kim S W, Jung H K, Kim M Y. Induction of p27 kip1 by 2, 4, 3′, 5′-tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells[J]. Archives of pharmacal research, 2008, 31: 1187-1194.
[6]Sahan-Firat S, Jennings B L, Yaghini F A, et al. 2, 3′, 4, 5′-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1[J]. American Journal of Physiology-Heart and Circulatory Physiology, 2010, 299(6): H1891-H1901.
[7]Jennings B L, Montanez D E, May M E, et al. Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats[J]. Cardiovascular drugs and therapy, 2014, 28: 145-161.
| Cell experiment [1]: | |
Cell lines | MCF-7 cells |
Preparation Method | Seed MCF-7 cells into 12-well plates at a density of 7.5×104 cells per well and performed this procedure in triplicate. The attached cells underwent treatment with 1μmol/L benzo[a]pyrene(BP) and received 0, 1, or 4μmol/L TMS. Cells underwent lysis by adding RIPA Lysis Buffer at time points of 4 hours, 12 hours, 24 hours, or 72 hours. Two identical samples of homogeneous cell lysate were placed into a 96-well plate and mixed with the same volume of Luminescence solution. Luminescence was measured using the microplate Luminometer. The viability assessment of cells exposed to BP alone involved performing the 72-hour treatment two times with triplicate assays for each experiment. The results are presented as percentages relative to the control with only DMSO solvent. |
Reaction Conditions | 0, 1, and 4μmol/L; 4, 12, 24, or 72h |
Applications | TMS exposure combined with BP increased overall CYP1A1 and CYP1B1 gene expression in a dose-dependent manner without influence on cell activity. |
| Animal experiment [2]: | |
Animal models | Spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats |
Preparation Method | The study used 36 male SHR rats aged three weeks and 36 age-matched Wistar-Kyoto rats. From 8 weeks of age every strain of rats was divided into two groups where one received daily intraperitoneal injections of TMS at 600μg/kg and the other group received DMSO vehicle solution (100μl). Samples were gathered for analysis when the rats reached 14 weeks old. Measure both systolic blood pressure and mean arterial pressure (MAP) two times each week starting at 4 weeks of age using a noninvasive method that involves a tail cuff. Rats underwent a week of acclimation to the blood pressure measuring device before commencing each experiment. |
Dosage form | 600μg/kg/day for 6 weeks; i.p. |
Applications | TMS reversed the increase in blood pressure and inhibited the increase in CYP1B1 activity of SHR. TMS maximally attenuated enhanced vascular reactivity, cardiovascular hypertrophy, endothelial and renal dysfunction, and cardiac and renal fibrosis in SHR. |
References: | |
| Cas No. | 24144-92-1 | SDF | |
| Synonyms | 2,3',4,5'Tetramethoxystilbene | ||
| Chemical Name | (E)-1-(3,5-dimethoxystyryl)-2,4-dimethoxybenzene | ||
| Canonical SMILES | COC1=CC(OC)=CC=C1/C=C/C2=CC(OC)=CC(OC)=C2 | ||
| Formula | C18H20O4 | M.Wt | 300.35 |
| Solubility | DMF: 30 mg/ml,DMF:PBS (pH 7.2)(1:1): 500 µ g/ml,DMSO: 20 mg/ml,Ethanol: 400 µ g/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3294 mL | 16.6472 mL | 33.2945 mL |
| 5 mM | 665.9 μL | 3.3294 mL | 6.6589 mL |
| 10 mM | 332.9 μL | 1.6647 mL | 3.3294 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)